НовостиBenzingaGuggenheim Maintains Buy on Rapport Therapeutics, Raises Price Target to $70 Guggenheim Maintains Buy on Rapport Therapeutics, Raises Price Target to $70 Benzinga 2026.10.21 13:30 (GMT+0) Открыть на Benzinga Другие новости